Exhibit 16.1
May 15, 2024
Securities and Exchange Commission
100 F Street, N.E. Washington DC 20549
Ladies and Gentlemen:
We have read Item 16F of in this Annual Report (Form 20-F) for the year ended December 31, 2023 of Scinai Immunotherapeutics Ltd. and are in agreement with the statements contained in the second, third and fourth paragraphs of Item 16F therein.
In addition, we have no basis to agree or disagree with other statements of the registrant contained in Item 16F of the above referenced filing.
| /s/ Kost Forer Gabbay & Kasierer |
Kost Forer Gabbay & Kasierer
A member firm of Ernst & Young Global
Tel Aviv, Israel